All In Biotech

Drug Trial Radar · NCT07581834

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jan 21, 2026

Primary completion

Dec 31, 2031

Study completion Jun 30, 2032

Sponsor

Lead sponsor
Fujian Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2- early breast cancer. The study planned to include 2000 HR +/HER2- early breast cancer patients who met the study criteria and were randomized in a 1:1 ratio to Column 1 and Column 2 stratified by nodal status (positive/negative), prior (neo) adjuvant chemotherapy (yes/no), and clinical/pathological stage (Stage II/III). Cohort 1 received dalcili 125 mg in combination with endocrine therapy for 2 years with dalcili; Cohort 2 received dalcili 100 mg in combination with endocrine therapy for 3 years with dalcili; treatment had to be discontinued until disease progression, intolerable adverse events, withdrawal of consent, or investigator judgment.

Conditions

  • Breast Diseases
  • Breast Neoplasms
  • Dalpiciclib
  • Endocrine Breast Diseases
  • CDK4/6 Inhibitor
  • HR+/HER2- Breast Cancer

Interventions

  • Dalpiciclib 125mgDrug

    Dalpiciclib: 125 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 2 years.

  • Dalpiciclib 100mgDrug

    Dalpiciclib: 100 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 3 years.

  • Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenDrug

    Endocrine therapy: endocrine therapy drugs selected by the investigator, including aromatase inhibitors (AIs), fulvestrant, tamoxifen, toremifene, etc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year invasive disease-free survivalTime frame: Observed from enrollment through 3 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hosptial

    Fuzhou, Fujian, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.